Canaccord raised its price target for Illumina shares, noting that revenue growth driven by clinical customers and NovaSeq X adoption is key to expansion goals.
2 reports, 1 independent
Updated Jul 31
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Canaccord raised its price target for Illumina shares, noting that revenue growth driven by clinical customers and NovaSeq X adoption is key to expansion goals.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- SomaLogic reported its revenue alongside NovaSeq X data.Sub-event
- Canaccord raised price target for Illumina, citing revenue growth from clinical customers and NovaSeq X adoption.
Keep exploring
The entities involved
-
Illumina
American company that develops systems for the analysis of genetic variation
Related events
Coverage
Newest first; wire copies grouped- dailypolitical.com
- Unknown outlet